$NAMS
NewAmsterdam Pharma Co N.V.

2024 Q3 Form 10-Q Financial Statement

#000095017024092281 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $29.11M $2.279M $9.562M
YoY Change 889.83% -76.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $18.41M $16.48M $13.70M
YoY Change 101.71% 20.24% 588.27%
% of Gross Profit
Research & Development $35.70M $38.38M $72.87M
YoY Change -17.68% -47.33% 138.24%
% of Gross Profit
Depreciation & Amortization $34.00K
YoY Change -5.56%
% of Gross Profit
Operating Expenses $54.11M $54.85M $86.61M
YoY Change 3.08% -36.66% 4250.51%
Operating Profit -$25.00M -$52.58M -$42.48M
YoY Change -49.55% 23.76%
Interest Expense $1.945M
YoY Change 137.8%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$16.65M -$39.01M -$75.10M
YoY Change -64.68% -48.06% 6303.16%
Income Tax -$1.000K $0.00
% Of Pretax Income
Net Earnings -$16.65M -$39.01M -$75.10M
YoY Change -64.68% -48.06% 6303.16%
Net Earnings / Revenue -57.18% -1711.58% -785.42%
Basic Earnings Per Share -$0.18 -$0.41 -$0.47
Diluted Earnings Per Share -$0.18 -$0.41 -$0.91
COMMON SHARES
Basic Shares Outstanding 90.02M 89.98M 82.06M
Diluted Shares Outstanding 94.75M 94.71M 82.06M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $383.5M
YoY Change 62212.33%
Cash & Equivalents $422.7M $430.7M $383.5M
Short-Term Investments
Other Short-Term Assets $5.769M
YoY Change 3753.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables $1.646M $2.134M
Total Short-Term Assets $437.9M $445.4M $389.3M
YoY Change 14.41% 50773.54%
LONG-TERM ASSETS
Property, Plant & Equipment $231.0K $234.0K $112.0K
YoY Change 108.93% -36.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $93.00K
YoY Change
Total Long-Term Assets $1.317M $1.338M $81.83M
YoY Change -98.36% -40.76%
TOTAL ASSETS
Total Short-Term Assets $437.9M $445.4M $389.3M
Total Long-Term Assets $1.317M $1.338M $81.83M
Total Assets $439.2M $446.7M $471.1M
YoY Change -5.18% 239.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.039M $5.275M $20.85M
YoY Change -74.71% 41032.15%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $64.00K
YoY Change 4.92%
Total Short-Term Liabilities $41.26M $45.31M $38.34M
YoY Change 18.19% 1989.57%
LONG-TERM LIABILITIES
Long-Term Debt $23.00K
YoY Change
Other Long-Term Liabilities $10.48M
YoY Change 101.02%
Total Long-Term Liabilities $10.50M
YoY Change 101.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.26M $45.31M $38.34M
Total Long-Term Liabilities $10.50M
Total Liabilities $60.33M $59.25M $48.83M
YoY Change 21.33% 593.08%
SHAREHOLDERS EQUITY
Retained Earnings -$466.4M -$449.7M
YoY Change
Common Stock $840.8M $832.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $378.9M $387.4M $422.3M
YoY Change
Total Liabilities & Shareholders Equity $439.2M $446.7M $471.1M
YoY Change -5.18% 239.17%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$16.65M -$39.01M -$75.10M
YoY Change -64.68% -48.06% 6303.16%
Depreciation, Depletion And Amortization $34.00K
YoY Change -5.56%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001936258
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41562
dei Entity Registrant Name
EntityRegistrantName
NewAmsterdam Pharma Company N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
dei Entity Address Address Line1
EntityAddressAddressLine1
Gooimeer 2-35
dei Entity Address City Or Town
EntityAddressCityOrTown
Naarden
dei Entity Address Country
EntityAddressCountry
NL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
1411 DC
dei City Area Code
CityAreaCode
+31
dei Local Phone Number
LocalPhoneNumber
(0) 35 206 2971
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
90015357
CY2024Q2 us-gaap Cash
Cash
430708000
CY2023Q4 us-gaap Cash
Cash
340450000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14644000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6341000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
445352000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
346791000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
234000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
554000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55000
CY2024Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
542000
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
170000
CY2024Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
8000
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
35000
CY2024Q2 us-gaap Assets
Assets
446690000
CY2023Q4 us-gaap Assets
Assets
347097000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5275000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16923000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10194000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11398000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6059000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8942000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
234000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
60000
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
23545000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
12574000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
45307000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49897000
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
222000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1019000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
328000
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
13394000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
7788000
CY2024Q2 us-gaap Liabilities
Liabilities
59251000
CY2023Q4 us-gaap Liabilities
Liabilities
58704000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90015357
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90015357
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82469768
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82469768
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
11151000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10173000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
821613000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
590771000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-449747000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316973000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4422000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4422000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
387439000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
288393000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
446690000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
347097000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2279000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1717000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3680000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10346000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38379000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34341000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80809000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74761000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16475000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9858000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30928000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17920000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
54854000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
44199000
us-gaap Operating Expenses
OperatingExpenses
111737000
us-gaap Operating Expenses
OperatingExpenses
92681000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-52575000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-42482000
us-gaap Operating Income Loss
OperatingIncomeLoss
-108057000
us-gaap Operating Income Loss
OperatingIncomeLoss
-82335000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4870000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4613000
us-gaap Investment Income Interest
InvestmentIncomeInterest
7953000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5556000
CY2024Q2 nams Change In Fair Value Of Earnout And Warrants
ChangeInFairValueOfEarnoutAndWarrants
-9692000
CY2023Q2 nams Change In Fair Value Of Earnout And Warrants
ChangeInFairValueOfEarnoutAndWarrants
350000
nams Change In Fair Value Of Earnout And Warrants
ChangeInFairValueOfEarnoutAndWarrants
29258000
nams Change In Fair Value Of Earnout And Warrants
ChangeInFairValueOfEarnoutAndWarrants
6525000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-994000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-72000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3412000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2995000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39007000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38291000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-132774000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-80309000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39007000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38291000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132774000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-80309000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
430066000
CY2023Q1 nams Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2698000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7663000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42018000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
398409000
CY2023Q2 nams Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
7514000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
105000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5606000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38291000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
373343000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
288393000
CY2024Q1 nams Issuance Of Ordinary Shares And Pre Funded Warrants Net Of Issuance Cost
IssuanceOfOrdinarySharesAndPreFundedWarrantsNetOfIssuanceCost
189966000
CY2024Q1 nams Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
19795000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-549000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7965000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93767000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
411803000
CY2024Q2 nams Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
6306000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8337000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39007000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
387439000
us-gaap Profit Loss
ProfitLoss
-132774000
us-gaap Profit Loss
ProfitLoss
-80309000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000
nams Noncash Rent Expense
NoncashRentExpense
3000
nams Noncash Rent Expense
NoncashRentExpense
3000
nams Change In Fair Value Of Derivative Earnout And Warrants
ChangeInFairValueOfDerivativeEarnoutAndWarrants
29258000
nams Change In Fair Value Of Derivative Earnout And Warrants
ChangeInFairValueOfDerivativeEarnoutAndWarrants
6525000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3412000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2995000
us-gaap Share Based Compensation
ShareBasedCompensation
16208000
us-gaap Share Based Compensation
ShareBasedCompensation
13174000
nams Increase Decrease In Prepayments And Other Receivables
IncreaseDecreaseInPrepaymentsAndOtherReceivables
8276000
nams Increase Decrease In Prepayments And Other Receivables
IncreaseDecreaseInPrepaymentsAndOtherReceivables
-4038000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11656000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1410000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1110000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1925000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3680000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4961000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108581000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61168000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
594000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
12000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-594000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000
nams Proceeds From Offering Of Ordinary Shares And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromOfferingOfOrdinarySharesAndPreFundedWarrantsNetOfIssuanceCosts
190481000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
515000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13421000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8621000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
440000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
105000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
989000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
202838000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8726000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
93663000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-52454000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3405000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1432000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
340450000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
467728000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
430708000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
416706000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
562000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
nams License Revenue Attributed From License Performance Obligations
LicenseRevenueAttributedFromLicensePerformanceObligations
5385000
CY2024Q2 nams License Revenue Attributed From R And D Performance Obligations
LicenseRevenueAttributedFromRAndDPerformanceObligations
2279000
CY2023Q2 nams License Revenue Attributed From R And D Performance Obligations
LicenseRevenueAttributedFromRAndDPerformanceObligations
1717000
nams License Revenue Attributed From R And D Performance Obligations
LicenseRevenueAttributedFromRAndDPerformanceObligations
3680000
nams License Revenue Attributed From R And D Performance Obligations
LicenseRevenueAttributedFromRAndDPerformanceObligations
4961000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2279000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1717000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3680000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10346000
CY2024Q2 nams Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
6994000
CY2023Q4 nams Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
2337000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2244000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2123000
CY2024Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
3272000
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1006000
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2134000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
875000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14644000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6341000
CY2024Q2 nams Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
6419000
CY2023Q4 nams Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
5945000
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2317000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3384000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1458000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2069000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10194000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11398000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15783509
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4541148
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.61
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
546403
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.27
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19778254
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
195399000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6888620
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
90930000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
6.3
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.414
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.384
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2024Q1 nams Volatility Ordinary Shares
VolatilityOrdinaryShares
0.10
nams Increase In Volatility Weight Percentage Of Ordinary Share Per Calendar Quarter
IncreaseInVolatilityWeightPercentageOfOrdinarySharePerCalendarQuarter
0.05
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8290000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5558000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16208000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13174000
nams Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Unrecognized Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsUnrecognizedCompensationCost
37700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y2M12D
CY2021Q3 nams Underlying Ordinary Shares1
UnderlyingOrdinaryShares1
838806
CY2023 nams Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Liability For Unvested Ordinary Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsLiabilityForUnvestedOrdinaryShares
100000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
608779
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
608779
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
596096
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
519999
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-39007000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-38291000
us-gaap Net Income Loss
NetIncomeLoss
-132774000
us-gaap Net Income Loss
NetIncomeLoss
-80309000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94711604
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94711604
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82064519
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82064519
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91611785
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91611785
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81850662
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81850662
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22478406
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17983485
CY2024Q2 nams Estimated Maximum Cancellation Fees
EstimatedMaximumCancellationFees
18100000
nams Percentage Of Development Costs Incurred
PercentageOfDevelopmentCostsIncurred
0.50
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
6200000
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-092281-index-headers.html Edgar Link pending
0000950170-24-092281-index.html Edgar Link pending
0000950170-24-092281.txt Edgar Link pending
0000950170-24-092281-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img55788779_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nams-20240630.htm Edgar Link pending
nams-20240630.xsd Edgar Link pending
nams-ex10_1.htm Edgar Link pending
nams-ex10_2.htm Edgar Link pending
nams-ex31_1.htm Edgar Link pending
nams-ex31_2.htm Edgar Link pending
nams-ex32_1.htm Edgar Link pending
nams-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nams-20240630_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending